Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.3
4.3
Journals
Antibiotics
Special Issues
Antibiotic Resistance and Therapy for Helicobacter pylori Infection
share announcement

Antibiotic Resistance and Therapy for Helicobacter pylori Infection

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 39914

Special Issue Editors

Prof. Dr. Stella I. Smith

E-Mail Website
Guest Editor
Molecular Biology and Biotechnology Department, Yaba, Nigeria
Interests: Campylobacter; Helicobacter; Arcobacter; Salmonella; Vibrio cholerae—epidemiology, antimicrobial susceptibility, and virulence
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Yoshio Yamaoka

E-Mail Website
Guest Editor
Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Idaigaoka, Hasama-machi, Yufu, Oita 879-5593, Japan
Interests: Helicobacter pylori; gastric cancer; virulence factors; epidemiology; human migration; antibiotics resistance; signal pathways; next generation sequencing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Helicobacter pylori infects approximately half of the world’s population and increasing antibiotic resistance is therefore a serious global threat to human health. There are several attributes that drive resistance to antibiotics; these can include phenotypic/physiological changes such as efflux/the impaired regulation of drug uptake, biofilm and coccoidal formation, and genotypic mechanisms of resistances. Most molecular methods of resistance occur due to mutations leading to treatment failures, diagnostic difficulties, and ambiguities in the clinical interpretation of therapeutic outcomes.

It is, therefore, pertinent to look at ways to improve/enhance treatment strategies so as to curb the increased antibiotic resistance of H. pylori and lead to its better management.

Potential topics for this Special Issue include but are not limited to:

  • Alternative and complementary therapies for the treatment of H. pylori in the context of antibiotic resistance;
  • New drug targets for H. pylori treatment in the post-antibiotic era;
  • Molecular-based antibiotic susceptibility testing techniques for H. pylori;
  • Mechanisms of H. pylori resistance: phenotypic/physiological changes in genomic mechanisms;
  • Supplementation of H. pylori antibiotic therapy using probiotics;
  • Clinical implication of drug resistance for H. pylori management.

The issue welcomes various types of submissions, such as original research papers, short communications, reviews, case reports, and perspectives.

Prof. Dr. Stella I. Smith
Prof. Dr. Yoshio Yamaoka
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • H. pylori
  • antibiotic resistance
  • alternative therapy
  • drug targets
  • probiotics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (12 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review, Other

5 pages, 189 KiB  
Editorial
Antibiotic Resistance and Therapy for Helicobacter pylori Infection
by Stella I. Smith and Yoshio Yamaoka
Antibiotics 2023, 12(12), 1669; https://doi.org/10.3390/antibiotics12121669 - 28 Nov 2023
Cited by 5 | Viewed by 2040
Abstract
Approximately half of the world’s population is estimated to be infected with Helicobacter pylori [...] Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)

Research

Jump to: Editorial, Review, Other

33 pages, 4558 KiB  
Article
Global Antimicrobial Resistance Gene Study of Helicobacter pylori: Comparison of Detection Tools, ARG and Efflux Pump Gene Analysis, Worldwide Epidemiological Distribution, and Information Related to the Antimicrobial-Resistant Phenotype
by Ricky Indra Alfaray, Batsaikhan Saruuljavkhlan, Kartika Afrida Fauzia, Roberto C. Torres, Kaisa Thorell, Selva Rosyta Dewi, Kirill A. Kryukov, Takashi Matsumoto, Junko Akada, Ratha-korn Vilaichone, Muhammad Miftahussurur and Yoshio Yamaoka
Antibiotics 2023, 12(7), 1118; https://doi.org/10.3390/antibiotics12071118 - 28 Jun 2023
Cited by 4 | Viewed by 3039
Abstract
We conducted a global-scale study to identify H. pylori antimicrobial-resistant genes (ARG), address their global distribution, and understand their effect on the antimicrobial resistance (AMR) phenotypes of the clinical isolates. We identified ARG using several well-known tools against extensive bacterial ARG databases, then [...] Read more.
We conducted a global-scale study to identify H. pylori antimicrobial-resistant genes (ARG), address their global distribution, and understand their effect on the antimicrobial resistance (AMR) phenotypes of the clinical isolates. We identified ARG using several well-known tools against extensive bacterial ARG databases, then analyzed their correlation with clinical antibiogram data from dozens of patients across countries. This revealed that combining multiple tools and databases, followed by manual selection of ARG from the annotation results, produces more conclusive results than using a single tool or database alone. After curation, the results showed that H. pylori has 42 ARG against 11 different antibiotic classes (16 genes related to single antibiotic class resistance and 26 genes related to multidrug resistance). Further analysis revealed that H. pylori naturally harbors ARG in the core genome, called the ‘Set of ARG commonly found in the Core Genome of H. pylori (ARG-CORE)’, while ARG-ACC—the ARG in the accessory genome—are exclusive to particular strains. In addition, we detected 29 genes of potential efflux pump-related AMR that were mostly categorized as ARG-CORE. The ARG distribution appears to be almost similar either by geographical or H. pylori populations perspective; however, some ARG had a unique distribution since they tend to be found only in a particular region or population. Finally, we demonstrated that the presence of ARG may not directly correlate with the sensitive/resistance phenotype of clinical patient isolates but may influence the minimum inhibitory concentration phenotype. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Graphical abstract

12 pages, 1760 KiB  
Article
Mutations Related to Antibiotics Resistance in Helicobacter pylori Clinical Isolates from Bangladesh
by Kartika Afrida Fauzia, Hafeza Aftab, Evariste Tshibangu-Kabamba, Ricky Indra Alfaray, Batsaikhan Saruuljavkhlan, Alain Cimuanga-Mukanya, Takashi Matsumoto, Phawinee Subsomwong, Junko Akada, Muhammad Miftahussurur and Yoshio Yamaoka
Antibiotics 2023, 12(2), 279; https://doi.org/10.3390/antibiotics12020279 - 31 Jan 2023
Cited by 12 | Viewed by 3094
Abstract
Current management of gastric inflammation involves the eradication of Helicobacter pylori. However, the effectiveness of commonly used antibiotics against H. pylori infection has decreased due to antibiotic resistance. Phenotypic-based diagnostics are laborious and finding the cause of resistance can be difficult. Therefore, [...] Read more.
Current management of gastric inflammation involves the eradication of Helicobacter pylori. However, the effectiveness of commonly used antibiotics against H. pylori infection has decreased due to antibiotic resistance. Phenotypic-based diagnostics are laborious and finding the cause of resistance can be difficult. Therefore, early detection and understanding of the underlying mechanism of this resistance are necessary. This study evaluated the mutations in the genes related to the Antimicrobial Resistance (AMR) of the clinical isolates from Bangladeshi subjects. Whole-genome sequencing was performed on 56 isolates and the genes (such as pbp1a, rdxA, ribF, fur, gyrA, gyrB, 23S rRNA, and infB) were extracted. The reads were assembled, and the SNPs were extracted by the latest pipeline for antibiotic mutation analysis, ARIBA. The mutations and the association with the antibiotic phenotypes were evaluated using Fisher’s exact test. In this study, the clarithromycin resistance rate was high, 39.3% (22/56), with the median MIC 24 mg/L ranging from 2 to 128 mg/L. The mutation of A2147G was significantly associated with resistance (p = 0.000018) but not in locus A2146G (p = 0.056). Levofloxacin also posed a high resistance. We observed that the mutation of D91N (but not D91Y) (p = 0.002) and N87K (p = 0.002) of gyrA was associated with levofloxacin resistance. Mutations in locus A343V (p = 0.041) of gyrB also showed a significant association. Meanwhile, in the pbp1a gene, several mutations might explain the resistance; they were G594fs (p = 0.036), K306R (p = 0.036), N562Y (p = 0.0006), and V45I (p = 0.018). The prevalence of metronidazole was exceptionally high (96.4%), and numerous mutations occurred in rdxA genes, including the truncation of genes. These results imply that the mutation in genes encoding the target protein of antibiotics remains the critical resistance mechanism in H. pylori. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

11 pages, 1885 KiB  
Article
A Bioluminescence-Based Drug Screen Identifies Activities of Fexinidazole and Its Metabolites against Helicobacter pylori
by Abdolhakim Mohamed, John N Chilingerian, Prerna Bali, Marygorret Obonyo and Anjan Debnath
Antibiotics 2022, 11(11), 1605; https://doi.org/10.3390/antibiotics11111605 - 11 Nov 2022
Cited by 3 | Viewed by 1930
Abstract
Helicobacter pylori is responsible for a wide range of gastric diseases, including gastric cancer and gastritis. With half of the world’s population infected by H. pylori and the current standard of care associated with suboptimal outcomes, a search for more effective drugs is [...] Read more.
Helicobacter pylori is responsible for a wide range of gastric diseases, including gastric cancer and gastritis. With half of the world’s population infected by H. pylori and the current standard of care associated with suboptimal outcomes, a search for more effective drugs is critical. To facilitate drug screening for H. pylori, we developed a microtiter plate-based compound screening method that is faster and can screen multiple compounds. We identified activities of fexinidazole and its sulfoxide and sulfone metabolites against H. pylori. Both fexinidazole and its metabolites exhibited equipotency against SS1, 60190, and G27 strains, which were about 3–6-fold more potent than the currently used metronidazole. We also determined the minimal inhibitory concentration (MIC) of metronidazole, fexinidazole, and its metabolites against these strains by a traditional agar plate-based method. While MIC values of fexinidazole and metronidazole were similar against all the strains, both sulfoxide and sulfone showed lower MIC values than metronidazole against SS1 and 60190. Given the recent FDA approval of fexinidazole, our data on the in vitro antibacterial activities of fexinidazole and its metabolites support further evaluation of this drug with the goal of producing an alternative nitro-based antimicrobial with good safety profiles for the treatment of H. pylori infection. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research, Other

14 pages, 392 KiB  
Review
The Influence of Helicobacter pylori on Human Gastric and Gut Microbiota
by Marcello Fiorani, Ege Tohumcu, Livio Enrico Del Vecchio, Serena Porcari, Giovanni Cammarota, Antonio Gasbarrini and Gianluca Ianiro
Antibiotics 2023, 12(4), 765; https://doi.org/10.3390/antibiotics12040765 - 16 Apr 2023
Cited by 14 | Viewed by 5550
Abstract
Helicobacter pylori is a Gram-negative bacterium that is able to colonize the human stomach, whose high prevalence has a major impact on human health, due to its association with several gastric and extra-gastric disorders, including gastric cancer. The gastric microenvironment is deeply affected [...] Read more.
Helicobacter pylori is a Gram-negative bacterium that is able to colonize the human stomach, whose high prevalence has a major impact on human health, due to its association with several gastric and extra-gastric disorders, including gastric cancer. The gastric microenvironment is deeply affected by H. pylori colonization, with consequent effects on the gastrointestinal microbiota, exerted via the regulation of various factors, including gastric acidity, host immune responses, antimicrobial peptides, and virulence factors. The eradication therapy required to treat H. pylori infection can also have detrimental consequences for the gut microbiota, leading to a decreased alpha diversity. Notably, therapy regimens integrated with probiotics have been shown to reduce the negative effects of antibiotic therapy on the gut microbiota. These eradication therapies combined with probiotics have also higher rates of eradication, when compared to standard treatments, and are associated with reduced side effects, improving the patient’s compliance. In light of the deep impact of gut microbiota alterations on human health, the present article aims to provide an overview of the complex interaction between H. pylori and the gastrointestinal microbiota, focusing also on the consequences of eradication therapies and the effects of probiotic supplementation. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

19 pages, 358 KiB  
Review
Treatment of Helicobacter pylori Infection in Patients with Penicillin Allergy
by Ligang Liu and Milap C. Nahata
Antibiotics 2023, 12(4), 737; https://doi.org/10.3390/antibiotics12040737 - 10 Apr 2023
Cited by 3 | Viewed by 4746
Abstract
Helicobacter pylori is among the prevalent causes of infections worldwide, and its resistance rate to antibiotics has been rising over time. Amoxicillin is the cornerstone for the treatment regimen. However, the prevalence of penicillin allergy ranges from 4% to 15%. In patients with [...] Read more.
Helicobacter pylori is among the prevalent causes of infections worldwide, and its resistance rate to antibiotics has been rising over time. Amoxicillin is the cornerstone for the treatment regimen. However, the prevalence of penicillin allergy ranges from 4% to 15%. In patients with true allergy, Vonoprazan-Clarithromycin-Metronidazole and bismuth quadruple therapy have demonstrated excellent eradication and high adherence rates. Vonoprazan-based therapy is administered less frequently and may be better tolerated than bismuth quadruple therapy. Therefore, vonoprazan-based therapy may be considered as a first-line therapy if accessible. Bismuth quadruple therapy can be used as the initial therapy when vonoprazan is unavailable. Levofloxacin or sitafloxacin-based regimens achieve a moderately high eradication rate. However, these are associated with potentially serious adverse effects and should only be used when other effective and safer regimens are unavailable. Cephalosporins such as cefuroxime have been used as an alternative to amoxicillin. Microbial susceptibility studies can guide the selection of appropriate antibiotics. PPI-Clarithromycin-Metronidazole fails to achieve a high eradication rate and should be used as a second-line therapy. PPI-Clarithromycin-Rifabutin should not be used because of low eradication rate and frequent adverse reactions. The choice of the most effective antibiotic regimen can enhance clinical outcomes in patients with H. pylori infection and penicillin allergy. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
15 pages, 926 KiB  
Review
Recombinant Helicobacter pylori Vaccine Delivery Vehicle: A Promising Tool to Treat Infections and Combat Antimicrobial Resistance
by Yakhya Dieye, Cheikh Momar Nguer, Fatou Thiam, Abou Abdallah Malick Diouara and Cheikh Fall
Antibiotics 2022, 11(12), 1701; https://doi.org/10.3390/antibiotics11121701 - 25 Nov 2022
Cited by 4 | Viewed by 2438
Abstract
Antimicrobial resistance (AMR) has become a global public health threat. Experts agree that unless proper actions are taken, the number of deaths due to AMR will increase. Many strategies are being pursued to tackle AMR, one of the most important being the development [...] Read more.
Antimicrobial resistance (AMR) has become a global public health threat. Experts agree that unless proper actions are taken, the number of deaths due to AMR will increase. Many strategies are being pursued to tackle AMR, one of the most important being the development of efficient vaccines. Similar to other bacterial pathogens, AMR in Helicobacter pylori (Hp) is rising worldwide. Hp infects half of the human population and its prevalence ranges from <10% in developed countries to up to 90% in low-income countries. Currently, there is no vaccine available for Hp. This review provides a brief summary of the use of antibiotic-based treatment for Hp infection and its related AMR problems together with a brief description of the status of vaccine development for Hp. It is mainly dedicated to genetic tools and strategies that can be used to develop an oral recombinant Hp vaccine delivery platform that is (i) completely attenuated, (ii) can survive, synthesize in situ and deliver antigens, DNA vaccines, and adjuvants to antigen-presenting cells at the gastric mucosa, and (iii) possibly activate desired compartments of the gut-associated mucosal immune system. Recombinant Hp vaccine delivery vehicles can be used for therapeutic or prophylactic vaccination for Hp and other microbial pathogens. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

11 pages, 586 KiB  
Review
Clinical Implication of Drug Resistance for H. pylori Management
by Erick A. Argueta, Jonathan J. C. Ho, Yousef Elfanagely, Erika D’Agata and Steven F. Moss
Antibiotics 2022, 11(12), 1684; https://doi.org/10.3390/antibiotics11121684 - 23 Nov 2022
Cited by 9 | Viewed by 2601
Abstract
Rates of antimicrobial-resistance among H. pylori strains are increasing worldwide, resulting in declining eradication rates with current therapies, especially those containing clarithromycin or levofloxacin. To improve H. pylori management, a paradigm shift is needed, from the empiric approaches formerly employed, to regimen selection [...] Read more.
Rates of antimicrobial-resistance among H. pylori strains are increasing worldwide, resulting in declining eradication rates with current therapies, especially those containing clarithromycin or levofloxacin. To improve H. pylori management, a paradigm shift is needed, from the empiric approaches formerly employed, to regimen selection based upon knowledge of local and patient-level antimicrobial susceptibility data. We review the mechanisms of H. pylori antimicrobial resistance and the available worldwide pattern of resistance to key antimicrobials used in H. pylori therapy. The practicalities and challenges of measuring susceptibility in clinical practice is discussed, including not only conventional culture-based techniques but also novel sequencing-based methods performed on gastric tissue and stool samples. Though clinical trials of “tailored” (susceptibility-based) treatments have yet to show the clear superiority of tailored over empiric regimen selection, the ability to measure and modify treatment based upon antimicrobial susceptibility testing is likely to become more frequent in clinical practice and should lead to improved H. pylori management in the near future. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

27 pages, 2030 KiB  
Review
Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature
by Enrico Celestino Nista, Antonio Pellegrino, Lucia Giuli, Marcello Candelli, Tommaso Schepis, Sara Sofia De Lucia, Veronica Ojetti, Francesco Franceschi and Antonio Gasbarrini
Antibiotics 2022, 11(10), 1452; https://doi.org/10.3390/antibiotics11101452 - 21 Oct 2022
Cited by 7 | Viewed by 3158
Abstract
Helicobacter pylori (H. pylori) resistance to antibiotics has increased worldwide in recent decades, especially to clarithromycin. As a result, the World Health Organization (WHO) identified clarithromycin-resistant H. pylori as a “high priority” pathogen in 2017. As international guidelines recommend empirical therapy [...] Read more.
Helicobacter pylori (H. pylori) resistance to antibiotics has increased worldwide in recent decades, especially to clarithromycin. As a result, the World Health Organization (WHO) identified clarithromycin-resistant H. pylori as a “high priority” pathogen in 2017. As international guidelines recommend empirical therapy as first-line treatment, it is crucial to know local resistance rates and history of antibiotic use to determine the most appropriate first-line antibiotic treatment. Italy is one of the European countries with the highest prevalence of H. pylori infection and the highest percentage of antibiotic-resistant H. pylori. The aim of this review is to summarize all data on H. pylori antibiotic resistance in Italy in order to quantify the current rate and determine the most effective therapeutic approach. The study confirms an elevated level of resistance to clarithromycin, metronidazole, and levofloxacin in Italy. In addition, our results show a satisfactory eradication rate for a bismuth-based regimen when used as first- or second-line treatment. Naive patients are also successfully treated with clarithromycin-based quadruple therapies. Considering the good results of bismuth-based therapy as recovery therapy, this argues for the potential use of clarithromycin quadruple therapy as a first-line treatment. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

14 pages, 520 KiB  
Review
Antimicrobial Resistance Profile by Metagenomic and Metatranscriptomic Approach in Clinical Practice: Opportunity and Challenge
by Langgeng Agung Waskito, Yudith Annisa Ayu Rezkitha, Ratha-korn Vilaichone, I Dewa Nyoman Wibawa, Syifa Mustika, Titong Sugihartono and Muhammad Miftahussurur
Antibiotics 2022, 11(5), 654; https://doi.org/10.3390/antibiotics11050654 - 13 May 2022
Cited by 6 | Viewed by 3767
Abstract
The burden of bacterial resistance to antibiotics affects several key sectors in the world, including healthcare, the government, and the economic sector. Resistant bacterial infection is associated with prolonged hospital stays, direct costs, and costs due to loss of productivity, which will cause [...] Read more.
The burden of bacterial resistance to antibiotics affects several key sectors in the world, including healthcare, the government, and the economic sector. Resistant bacterial infection is associated with prolonged hospital stays, direct costs, and costs due to loss of productivity, which will cause policy makers to adjust their policies. Current widely performed procedures for the identification of antibiotic-resistant bacteria rely on culture-based methodology. However, some resistance determinants, such as free-floating DNA of resistance genes, are outside the bacterial genome, which could be potentially transferred under antibiotic exposure. Metagenomic and metatranscriptomic approaches to profiling antibiotic resistance offer several advantages to overcome the limitations of the culture-based approach. These methodologies enhance the probability of detecting resistance determinant genes inside and outside the bacterial genome and novel resistance genes yet pose inherent challenges in availability, validity, expert usability, and cost. Despite these challenges, such molecular-based and bioinformatics technologies offer an exquisite advantage in improving clinicians’ diagnoses and the management of resistant infectious diseases in humans. This review provides a comprehensive overview of next-generation sequencing technologies, metagenomics, and metatranscriptomics in assessing antimicrobial resistance profiles. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

Other

8 pages, 438 KiB  
Perspective
Helicobacter pylori Infection: Antibiotic Resistance and Solutions for Effective Management in Africa
by Mashiko Setshedi and Stella I. Smith
Antibiotics 2023, 12(6), 969; https://doi.org/10.3390/antibiotics12060969 - 26 May 2023
Cited by 4 | Viewed by 2137
Abstract
Helicobacter pylori (H. pylori) infection is ubiquitous worldwide, with prevalence rates of greater than 70% in Africa. Symptomatic patients present with foregut gastrointestinal symptoms which can be readily diagnosed with standardized non-invasive or invasive tests. The biggest challenge, however, is in [...] Read more.
Helicobacter pylori (H. pylori) infection is ubiquitous worldwide, with prevalence rates of greater than 70% in Africa. Symptomatic patients present with foregut gastrointestinal symptoms which can be readily diagnosed with standardized non-invasive or invasive tests. The biggest challenge, however, is in the management of this condition with rising antimicrobial resistance rates to most of the antibiotics recommended for therapy. This is a problem worldwide, but more specifically in Africa, where the socio-economic and political climate is such that eradication of this organism seems impossible. Furthermore, the recommended antimicrobial susceptibility testing for drug resistance is not widely available in Africa due to the lack of infrastructural as well as human resources. With the widespread unregulated use of antibiotics in some parts of Africa, the figures of antimicrobial resistance are likely to soar. In the face of these significant challenges, this ‘perspectives’ article aims to address the issue of antimicrobial resistance in Africa, by providing achievable and targeted goals to curb the spread of infection and rising antimicrobial resistance. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

14 pages, 1084 KiB  
Systematic Review
The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis
by Ligang Liu, Fang Li, Hekai Shi and Milap C. Nahata
Antibiotics 2023, 12(2), 346; https://doi.org/10.3390/antibiotics12020346 - 7 Feb 2023
Cited by 10 | Viewed by 3944
Abstract
The eradication of Helicobacter pylori (H. pylori) infection remains challenging due to increasing bacterial resistance. Resistance rates to clarithromycin, metronidazole, and levofloxacin were higher than 30% in the USA, making current therapies less effective. Vonoprazan triple therapy (VAC) has demonstrated similar efficacy and [...] Read more.
The eradication of Helicobacter pylori (H. pylori) infection remains challenging due to increasing bacterial resistance. Resistance rates to clarithromycin, metronidazole, and levofloxacin were higher than 30% in the USA, making current therapies less effective. Vonoprazan triple therapy (VAC) has demonstrated similar efficacy and safety profiles compared to PPI-based triple therapy (PPI). However, the eradication rate of vonoprazan dual therapy (VA) for H. pylori infection in comparison to VAC, and PPI was poorly established. Electronic databases were searched up to 6 October 2022, to identify studies examining the safety and efficacy of VA compared to VAC and PPI. Six studies were included. For empiric therapies among treatment naïve patients, VA, VAC, and PPI did not achieve high cure rates (>90%). The comparative efficacy ranking showed VAC was the most effective therapy, followed by VA, and PPI. The results were similar for clarithromycin-resistant infections. The comparative safety ranking showed VA ranked first, whereas PPI triple therapy was the least safe regimen. These findings should guide the selection of the most effective and safe treatment and conduct additional studies to determine the place of vonoprazan dual versus triple therapies in patients with H. pylori from various countries across the world. Full article
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-12
Back to TopTop